Benhalima Katrien, Robyns Karolien, Van Crombrugge Paul, Deprez Natascha, Seynhave Bruno, Devlieger Roland, Verhaeghe Johan, Mathieu Chantal, Nobels Frank
Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Endocrinology, OLV ziekenhuis Aalst-Asse-Ninove, Moorselbaan 164, 9300, Aalst, Belgium.
BMC Pregnancy Childbirth. 2015 Oct 23;15:271. doi: 10.1186/s12884-015-0706-x.
Our aim was to evaluate the difference in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes (GDM).
Retrospective analysis of the medical files from 2010-2013 of women with GDM diagnosed with the Carpenter & Coustan criteria attending two clinics, one in a university and another in a non-university hospital. Characteristics associated with insulin use were analyzed. Multivariable logistic regression was used to adjust for confounders. For women attending the university hospital, indices of insulin sensitivity such as the reciprocal of the homeostasis model assessment of insulin resistance (1/HOMA-IR) and an index of beta-cell function, the Insulin Secretion-Sensitivity Index-2 (ISSI-2) were calculated.
Over a 4 year period, 601 women were identified with GDM of whom 22.9% were obese at first prenatal visit. 24.2% needed insulin. Insulin did not prevent adverse outcomes, as women on insulin had higher rates of large-for-gestational age infants (LGA) (28.5% vs. 13.1 %, p < 0.0001) and more cesarean sections (44.1% vs. 27.0%, p = 0.001), remaining significant after adjustment for confounders. Compared to diet-treated women, women on insulin more often had an ethnic minority background (33.3 % vs. 21.6%, p = 0.004), more often had a history of GDM (21.5% vs. 10.4%, p = 0.002), were more often multiparous (59.3% vs. 47.6%, p = 0.044) and were diagnosed with GDM earlier in pregnancy (weeks 25.3 ± 4.9 vs. 27.1 ± 3.7, p < 0.0001). When undergoing an oral glucose tolerance test, women treated with insulin had a higher fasting glycaemia (97.6 ± 18.8 vs.87.7 ± 10.3, p < 0.0001), a higher 1-hour glycaemia (197.7 ± 30.1 vs.184.5 ± 25.8, p < 0.0001), a higher 2-hour glycaemia (185.2 ± 28.5 vs. 175.0 ± 22.8, p < 0.0001), more often 3 and 4 abnormal values (58.1% vs. 37.8%, p < 0.0001 and 24.8% vs. 7.7%, p < 0.0001) and higher HbA1c levels (5.5 ± 0.6 vs 5.2 ± 0.5, p < 0.0001). ISSI-2 (1.3 ± 0.5 vs. 1.7 ± 0.5, p < 0.0001) and 1/HOMA-IR [0.01 (0.001-0.002) vs. 0.02 (0.01-0.03), p = 0.027] were lower in women on insulin. Women on insulin more often received corticoids in preparation of preterm delivery (11.0% vs. 2.4%, p < 0.0001).
Compared to diet-treated women with GDM, women treated with insulin have a higher risk profile, impaired beta-cell function and lower insulin sensitivity. Rates of LGA and cesarean sections were higher in insulin-treated women.
我们的目的是评估接受胰岛素治疗和饮食治疗的妊娠期糖尿病(GDM)女性在妊娠结局和特征方面的差异。
对2010 - 2013年期间根据卡彭特和库斯坦标准诊断为GDM的女性的医疗档案进行回顾性分析,这些女性来自两家诊所,一家在大学医院,另一家在非大学医院。分析与胰岛素使用相关的特征。采用多变量逻辑回归对混杂因素进行校正。对于在大学医院就诊的女性,计算胰岛素敏感性指标,如胰岛素抵抗稳态模型评估的倒数(1/HOMA - IR)和β细胞功能指标胰岛素分泌 - 敏感性指数 - 2(ISSI - 2)。
在4年期间,共识别出601例GDM女性,其中22.9%在首次产前检查时肥胖。24.2%需要胰岛素治疗。胰岛素并不能预防不良结局,因为接受胰岛素治疗的女性发生大于胎龄儿(LGA)的比例更高(28.5%对13.1%,p < 0.0001),剖宫产率更高(44.1%对27.0%,p = 0.001),在对混杂因素进行校正后仍具有显著性差异。与接受饮食治疗的女性相比,接受胰岛素治疗的女性更常具有少数族裔背景(33.3%对21.6%,p = 0.004),更常有GDM病史(21.5%对10.4%,p = 0.002),更常为经产妇(59.3%对47.6%,p = 0.044),且在妊娠早期被诊断为GDM(25.3 ± 4.9周对27.1 ± 3.7周,p < 0.0001)。在进行口服葡萄糖耐量试验时,接受胰岛素治疗的女性空腹血糖更高(97.6 ± 18.8对87.7 ± 10.3,p < 0.0001),1小时血糖更高(197.7 ± 30.1对184. — 5 ± 25.8,p < 0.0001),2小时血糖更高(185.2 ± 28.5对175.0 ± 22.8,p < 0.0001),更常出现3项和4项异常值(58.1%对37.8%,p < 0.0001和24.8%对7.7%,p < 0.0001),且糖化血红蛋白水平更高(5.5 ± 0.6对5.2 ± 0.5,p < 0.0001)。接受胰岛素治疗的女性的ISSI - (1.3 ± 0.对1.7 ± 0.5,p < 0.0001)和1/HOMA - IR [0.01(0.001 - 0.002)对0.02(0.01 - 0.03),p = 0.027]更低。接受胰岛素治疗的女性在准备早产时更常接受皮质类固醇治疗(11.0%对2.4%,p < 0.0001)。
与接受饮食治疗的GDM女性相比,接受胰岛素治疗的女性具有更高的风险特征、β细胞功能受损和更低的胰岛素敏感性。接受胰岛素治疗的女性中LGA和剖宫产的发生率更高。